Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182151 · ClinicalTrials.gov registry record
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
A clinical trial, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- 8
- Enrollment target
NCT05182151: Clinical Trial study, sponsored by Medical University of South Carolina.
NCT05182151 is a clinical trial that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05182151 was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's disease (PD). Many individuals with Parkinson's disease experiencing fluctuations in the severity of their movement problems and medication "off" time. "Off" time refers to periods of the day between doses of PD medication when your motor symptoms (e.g., tremor, stiffness, slowness, walking problems, etc.) are worse and interfere with your ability to complete tasks of daily living. The investigational drug, Istradefylline, is an FDA-approved medication to treat motor fluctuations and "off" time in PD. The purpose of this study is to investigate whether people with Parkinson's disease (PD) who are treated with istradefylline (ISD) show improvements in motivation and apathy over a 12-week period. Specifically, we wish to see whether people with PD who are treated with ISD engage in more physical and recreational activities, such as hobbies and other interests.
Primary Outcome
telephone survey
Interventions
- DRUG Istradefylline 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2023-12-01 |
Why NCT05182151 stopped before completion
NCT05182151 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Istradefylline 40 mg is the first listed.
NCT05182151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05182151 about?
NCT05182151 is a clinical study titled "Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.". Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's dise...
What is the current status of trial NCT05182151?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2022-07-29. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05182151?
The interventions under investigation include: Istradefylline 40 mg (DRUG).
Who is sponsoring clinical trial NCT05182151?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI